Rillieux La Pape

Researchers are evaluating the role of hospital pharmacists in supporting patients who begin oral cancer treatments at healthcare facilities. The study aims to measure how pharmaceutical monitoring at the start of oral therapy can improve patient compliance, manage side effects, and ensure adherence compared to patients who do not receive this monitoring. The focus is on patients with solid tumors starting oral therapy, excluding those with blood cancers. The study involves two main procedures. First, a pharmaceutical consultation occurs when the patient receives their first oral cancer prescription, offering an optimized medication review. Then, during treatment renewal, the hospital pharmacist contacts the patient's local pharmacy to coordinate care and monitor treatment adherence. This follow-up helps detect issues like treatment non-renewal or side effects, which are recorded in an observation log. Participants will be monitored for compliance using the Girerd questionnaire at three and six months after starting treatment. The study tracks patient adherence, side-effect management, and coordination between hospital and local pharmacies. The total participation time depends on the duration of oral therapy and follow-up assessments at specified intervals to evaluate treatment observance and support.

Researchers are evaluating the Lync4 device implanted in the toes to treat arthritis and correct bone misalignments such as mallet toes, claw toes, and hammer toes. The study aims to confirm the clinical benefits, performance, and safety of this device, focusing mainly on restoring forefoot function and bone alignment. The primary goal is to assess improvements in functional capacity using the AOFAS-LMIS score at 3 to 4 months after surgery. The treatment involves using the Lync4 intramedullary osteosynthesis implantable device during surgery for arthritis and bone alignment correction. Some additional surgical procedures like flexor release/tenotomy, MTP arthrolysis/extensor lengthening, tendon transfers, or phalangeal osteotomy may be performed alongside. The study includes 76 feet undergoing this intervention, with follow-up visits scheduled at 3 to 4 months post-operation and an optional 6-month visit if bone union has not occurred. Participants will be monitored through clinical and radiographic examinations to evaluate pain reduction, bone consolidation, functional recovery, and any adverse events or device defects. The main outcome measured is the EFAS score at 3 to 4 months post-surgery, alongside secondary assessments of pain changes, bone healing, and safety throughout the follow-up period. Participants are expected to comply with surgeon recommendations and sign informed consent, with adult patients involved in the study.

Researchers are investigating treatments for advanced metastatic adenocarcinoma of the stomach and gastro-esophageal junction, a serious cancer with low survival rates. Current treatments include chemotherapy combinations and immunotherapy, which have improved outcomes for some patients. However, when cancer progresses after these therapies, options are limited, and new approaches are needed to extend survival and maintain quality of life. This international Phase III trial (FRUQUITAS) tests whether adding fruquintinib, an anti-angiogenic drug, to the oral chemotherapy drug trifluridine/tipiracil can improve survival for patients whose cancer has continued to grow despite prior treatments. The study compares two groups: one receiving trifluridine/tipiracil alone and the other receiving trifluridine/tipiracil combined with fruquintinib. Trifluridine/tipiracil is given orally twice daily on days 1 to 5 and days 8 to 12 of a 28-day cycle, repeated until disease progression or unacceptable side effects. Fruquintinib is taken orally once daily for 21 days of a 28-day cycle, also continued until progression or toxicity. This combination aims to block the tumor's blood supply while providing chemotherapy. The trial evaluates if this approach extends overall survival compared to chemotherapy alone. Participants will be adults with metastatic adenocarcinoma who have received two or three previous treatment lines. They will undergo regular assessments including tumor evaluations per RECIST criteria, blood tests to monitor organ function, and safety checks. Researchers will measure overall survival up to 18 months after starting treatment. The study involves ongoing monitoring for side effects and treatment tolerance, with participation lasting until disease progression, unacceptable toxicity, or withdrawal. Biological samples may also be collected for further research, and informed consent is required before enrollment.